1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin

BACKGROUND: Cefiderocol (CFDC) is the first siderophore cephalosporin approved (US and EU) for a broad range of infections caused by Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (ENT) and non-fermenters (NFs). Bacteremia is a serious manifestation of GN infection and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, David PatersonDavid PatersonMasahiro, Toyoizumi, Kiichiro, Matsunaga, Yuko, Echols, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777096/
http://dx.doi.org/10.1093/ofid/ofaa439.1468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777096/
http://dx.doi.org/10.1093/ofid/ofaa439.1468

Ejemplares similares